Outcomes Research in Rheumatic Diseases

风湿性疾病的结果研究

• 批准号: 10254297
• 负责人: DINESH KHANNA
• 金额: $ 13.28万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254297
• 关键词: Address; Advocate; Antibody-drug conjugates; Area; Autoimmunity; Award; Blood; Charge; Clinical; Clinical Research; Clinical Trials Design; Computerized Medical Record; Consensus; Cutaneous; Data; Development; Diffuse; Discipline; Documentation; Dose; Double-Blind Method; Ensure; Exercise; Faculty; Fostering; Foxes; Funding; Future; Goals; Grant; Growth; Health Personnel; Immune Tolerance; Information Resources Management; Information Systems; Institution; International; Internet; Interstitial Lung Diseases; Journals; Leadership; Link; Measurement; Measures; Medical Students; Medicine; Mentors; Michigan; Molecular Profiling; National Institute of Allergy and Infectious Disease; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Outcome Measure; Outcomes Research; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Peer Review; Phase; Pilot Projects; Placebos; Postdoctoral Fellow; Protocols documentation; Publishing; Randomized Controlled Trials; Reporting; Research; Research Personnel; Research Project Grants; Research Support; Research Training; Rheumatism; Role; Safety; Scleroderma; Secure; Self Efficacy; Self Management; Skin; Systemic Scleroderma; T-Lymphocyte; TNFRSF8 gene; Techniques; Time; Training; Training Programs; United States National Institutes of Health; Universities; base; career; clinical practice; comparative effectiveness study; improved; indexing; interest; next generation; patient oriented research; patient-clinician communication; point of care; preservation; primary outcome; professor; programs; prospective; recruit; response; safety study; self-management program; skills; subcutaneous; undergraduate student

Project Summary/Abstract Outcomes research in rheumatic diseases Dr. Dinesh Khanna is a professor of medicine at the University of Michigan (UM) and director of the UM Scleroderma Program. He seeks the extension of the K24 Mid-Career Investigator Award in Patient-Oriented Research (POR) to continue this successful research program while dedicating significant time for mentoring the next generation of undergraduates, medical students, residents, clinical and post-doctoral fellows, and junior faculty trainees. The goals of the K24 renewal application are to support the candidate's continued impact as a mentor and assume leadership roles in collaborative POR programs, to continue the growth of a research training program for POR at the UM, and to recruit new mentees who are interested in POR. Since the successful funding of the initial K24 grant, the candidate has actively mentored trainees and junior faculty on different POR projects who have published in peer-reviewed journals and received independent funding. The candidate has launched successful collaborative links with other disciplines and institutions in the pursuit of program excellence, and there is strong institutional support to create this program. The K24 grant would preserve 30% of the candidate's effort and relieve future clinical and administrative responsibilities. A diverse portfolio of currently funded research opportunities exists for future trainees in POR. The research proposed includes four current projects and one new project addressing POR areas of patient reported outcomes, outcome measures, and clinical trial design. The currently funded studies include: 1) Taking charge of systemic sclerosis: Improving patient outcomes through self-management (funded by PCORI); 2) Development of a systemic sclerosis-associated interstitial lung disease combined response index (R01, funded by NIH/NIAMS); 3) An investigator-initiated, multicenter international phase II pilot study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial (funded by NIH/NIAID, University of Michigan Autoimmunity Center of Excellence and Bristol Myers Squibb); and 4) A dose escalation safety study of brentuximab vedotin in diffuse dutaneous Systemic Sclerosis (funded by NIH/NIAID/Immune Tolerance Network). The aim of the new proposed study is to implementation the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) in clinical practice using a pilot cluster randomized controlled trial.

项目概要/摘要 风湿性疾病的结果研究 Dinesh Khanna 博士是密歇根大学 (UM) 医学教授兼 UM 主任 他寻求将 K24 职业生涯中期研究者奖延期到以患者为导向的领域。 研究 (POR) 继续这一成功的研究计划，同时投入大量时间进行指导 下一代本科生、医学生、住院医生、临床和博士后研究员，以及 K24 续签申请的目标是支持候选人的继续学习。 作为导师发挥影响力，并在协作 POR 项目中发挥领导作用，以继续发展 在 UM 开展 POR 研究培训计划，并招募对 POR 感兴趣的新学员。 自从成功资助第一笔 K24 拨款以来，该候选人积极指导学员和初级学员 参与不同 POR 项目的教师，他们在同行评审的期刊上发表过文章并获得了独立的 候选人已与其他学科和机构建立了成功的合作联系。 追求卓越的计划，并且有强大的机构支持来创建该计划。 将节省候选人 30% 的精力并减轻未来的临床和行政责任。 目前资助的研究机会多种多样，可供 POR 未来的学员使用。 拟议的研究包括四个当前项目和一个针对患者 POR 领域的新项目 报告的结果、结果测量和临床试验设计目前资助的研究包括：1) 负责系统性硬化症：通过自我管理改善患者的治疗结果（由 2) 系统性硬化症相关间质性肺疾病综合反应指数的制定 （R01，由 NIH/NIAMS 资助）；3) 一项由研究者发起的多中心国际 II 期试点研究 评估皮下注射阿巴西普与安慰剂治疗弥漫性皮肤系统性硬化症的效果——双盲、 安慰剂对照、随机对照试验（由 NIH/NIAID、密歇根大学自身免疫研究所资助） 卓越中心和百时美施贵宝）；4) brentuximab vedotin 的剂量递增安全性研究 弥漫性硬化症（由 NIH/NIAID/免疫耐受网络资助）。 新提议的研究旨在实施 NIH 患者报告结果测量信息 系统 (PROMIS®) 在临床实践中使用试点集群随机对照试验。